Iliac Artery Stenosis
1
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Terumo MedicalGermany - Leverkusen
1 programMisago® RX Self-expanding Peripheral StentN/A1 trial
Active Trials
Micro Medical DevicesCA - Calabasas
1 programTreatment of primary iliac artery stenosis and/or occlusive lesionsN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Boston ScientificEpic™ Nitinol Stent System
Terumo MedicalMisago® RX Self-expanding Peripheral Stent
Micro Medical DevicesTreatment of primary iliac artery stenosis and/or occlusive lesions
Clinical Trials (3)
Total enrollment: 382 patients across 3 trials
EPIC Nitinol Stent System in the Treatment of Atherosclerotic Lesions in Iliac Arteries
Start: May 2009Est. completion: Dec 2013125 patients
Phase 3Completed
Misago® RX Self-expanding Peripheral Stent for Common and/or External Iliac Artery
Start: Aug 2022Est. completion: Sep 202675 patients
N/AActive Not Recruiting
Evaluation of the Efficacy and Safety of the Application of BeGraft Peripheral Stent Graft System
Start: Sep 2019Est. completion: Aug 2025182 patients
N/AActive Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.